PPARγ2 Pro12Ala polymorphism is associated with sustained virological response in HIV/HCV-coinfected patients under HCV therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 67, Issue 2, 2014, Pages 113-119

  Fernández Rodríguez, Amanda ^a   Berenguer, Juan ^b,c   Rallón, Norma ^d   Jiménez Sousa, María A ^a   López, Juan Carlos ^b   Soriano, Vicente ^e   García Álvarez, Mónica ^a   Cosín, Jaime ^a   Martínez, Paula ^d   Guzmán Fulgencio, María ^a   Miralles, Pilar ^b   Benito, José Miguel ^d   Resino, Salvador ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

AIDS; Chronic hepatitis C; HCV therapy; PPAR 2; Single nucleotide polymorphism

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; ALLELE; ANTIVIRAL THERAPY; ARTICLE; DECISION TREE; DOMINANT INHERITANCE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC POLYMORPHISM; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 3; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD; ANIMAL; BLOOD; COMPLICATION; DRUG COMBINATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; TIME;

ADULT; ANIMALS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TIME; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84922291138     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000282     Document Type: Article

References (50)

1. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet. 2003; 362: 22-29.
2. Macias J, Berenguer J, Japon MA, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology. 2009; 50: 1056-1063.
3. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008; 48: 590-598.
4. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A metaanalysis. Clin Infect Dis. 2001; 33: 562-569.
5. Operskalski EA, Kovacs A. HIV/HCV co-infection: Pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep. 2011; 8: 12-22.
6. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology. 2009; 49: 1335-1374.
7. Rockstroh JK, Bhagani S. Managing HIV/hepatitis C co-infection in the era of direct acting antivirals. BMC Med. 2013; 11: 234.
8. Sulkowski MS. HCV therapy in HIV-infected patients. Liver Int. 2013; 33 (suppl 1): 63-67.
9. Delemos AS, Chung RT. Hepatitis C treatment: An incipient therapeutic revolution. Trends Mol Med. 2014; 20: 315-321.
10. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 368: 1878-1887.
11. Naggie S, Sulkowski MS. Management of patients coinfected with HCV and HIV: A close look at the role for direct-Acting antivirals. Gastroenterology. 2012; 142: 1324.e3-1334 e3.
12. Calvaruso V, Craxi A. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int. 2012; 32 (suppl 1): 2-8.
13. Kotler DP. Hepatitis C, human immunodeficiency virus and metabolic syndrome: Interactions. Liver Int. 2009; 29(suppl 2): 38-46.
14. Ryan P, Resino S, Miralles P, et al. Insulin resistance impairs response to interferon plus ribavirin in patients coinfected with HIV and hepatitis C virus. J Acquir Immune Defic Syndr. 2010; 55: 176-181.
15. Eslam M, Lopez-Cortes LF, Romero-Gomez M. The role of insulin resistance in HIV/hepatitis C virus-coinfected patients. Curr Opin HIV AIDS. 2011; 6: 553-558.
16. Soriano V, Poveda E, Vispo E, et al. Pharmacogenetics of hepatitis C. J Antimicrob Chemother. 2012; 67: 523-529.
17. Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab. 2012; 23: 351-363.
18. Tontonoz P, SB. Fat and beyond: The diverse biology of PPARgamma. Annu Rev Biochem. 2008; 77: 289-312.
19. Jeninga EH, Gurnell M, Kalkhoven E. Functional implications of genetic variation in human PPARgamma. Trends Endocrinol Metab. 2009; 20: 380-387.
20. Saraf N, Sharma PK, Mondal SC, et al. Role of PPARγ2 transcription factor in thiazolidinedione-induced insulin sensitization. J Pharm Pharmacol. 2012; 64: 161-171.
21. Otake K, Omoto S, Yamamoto T, et al. HIV-1 Nef protein in the nucleus influences adipogenesis as well as viral transcription through the peroxisome proliferator-Activated receptors. AIDS. 2004; 18: 189-198.
22. Shrivastav S, Kino T, Cunningham T, et al. Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-Activated receptor {gamma} and inhibits adipocyte differentiation: Implications for HIV-Associated lipodystrophy. Mol Endocrinol. 2008; 22: 234-247.
23. Diaz-Delfin J, Domingo P, Mateo MG, et al. Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antimicrob Agents Chemother. 2012; 56: 3369-3375.
24. Mencarelli A, Francisci D, Renga B, et al. Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-gamma-dependent manner. Antivir Ther. 2012; 17: 669-678.
25. Kim K, Kim KH, Ha E, et al. Hepatitis C virus NS5A protein increases hepatic lipid accumulation via induction of activation and expression of PPARgamma. FEBS lett. 2009; 583: 2720-2726.
26. Kim KH, Hong SP, Kim K, et al. HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARgamma. Biochem Biophys Res Commun. 2007; 355: 883-888.
27. Huguenin GV, Rosa G. The Ala allele in the PPAR-gamma2 gene is associated with reduced risk of type 2 diabetes mellitus in Caucasians and improved insulin sensitivity in overweight subjects. Br J Nutr. 2010; 104: 488-497.
28. Gouda HN, Sagoo GS, Harding AH, et al. The association between the peroxisome proliferator-Activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: A HuGE review and metaanalysis. Am J Epidemiol. 2010; 171: 645-655.
29. Saumoy M, Veloso S, Alonso-Villaverde C, et al. PPARgamma Pro12Ala polymorphism in HIV-1-infected patients with HAART-related lipodystrophy. Curr HIV Res. 2009; 7: 533-540.
30. Hung YP, Lee NY, Lin SH, et al. Effects of PPARgamma and RBP4 gene variants on metabolic syndrome in HIV-infected patients with antiretroviral therapy. PLoS One. 2012; 7: E49102.
31. Nazih H, Raffi F, Taieb A, et al. Peroxisome proliferator activating receptor alpha and gamma polymorphisms and metabolic abnormalities in HIV-infected patients receiving highly active antiretroviral therapy: The ANRS CO8 APROCO-COPILOTE study. AIDS Res Hum Retroviruses. 2012; 28: 393-399.
32. Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002; 155: 645-653.
33. Resino S, Seoane JA, Bellon JM, et al. An artificial neural network improves the non-invasive diagnosis of significant fibrosis in HIV/HCV coinfected patients. J Infect. 2011; 62: 77-86.
34. Tuma P, Medrano J, Resino S, et al. Incidence of liver cirrhosis in HIVinfected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. Antivir Ther. 2010; 15: 881-886.
35. Purcell S, Neale B, Todd-Brown K, et al. PLINK: A tool set for wholegenome association and population-based linkage analyses. Am J Hum Genet. 2007; 81: 559-575.
36. Heikkinen S, Argmann C, Feige JN, et al. The Pro12Ala PPARgamma2 variant determines metabolism at the gene-environment interface. Cell metab. 2009; 9: 88-98.
37. Luan J, Browne PO, Harding AH, et al. Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes. 2001; 50: 686-689.
38. Memisoglu A, Hu FB, Hankinson SE, et al. Interaction between a peroxisome proliferator-Activated receptor gamma gene polymorphism and dietary fat intake in relation to body mass. Hum Mol Genet. 2003; 12: 2923-2929.
39. Jimenez-Sousa MA, Fernandez-Rodriguez A, Guzman-Fulgencio M, et al. Meta-Analysis: Implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med. 2013; 11: 6.
40. Fernandez-Rodriguez A, Rallon N, Berenguer J, et al. Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients. AIDS. 2013; 27: 163-173.
41. Holmes JA, Desmond PV, Thompson AJ. Redefining baseline demographics: The role of genetic testing in hepatitis C virus infection. Clin Liver Dis. 2011; 15: 497-513.
42. Stumvoll M, Haring H. The peroxisome proliferator-Activated receptorgamma2 Pro12Ala polymorphism. Diabetes. 2002; 51: 2341-2347.
43. Ma J, Li Y, Zhou F, et al. Meta-Analysis of association between the Pro12Ala polymorphism of the peroxisome proliferator-Activated receptor-gamma2 gene and diabetic retinopathy in Caucasians and Asians. Mol Vis. 2012; 18: 2352-2360.
44. Liu G, Zhou TB, Jiang Z, et al. Relationship between PPARgamma Pro12Ala gene polymorphism and type 2 diabetic nephropathy risk in Asian population: Results from a meta-Analysis. J Recep Signal Transduct Res. 2014; 34: 131-136.
45. Zhou TB, Guo XF, Yin SS. Association of peroxisome proliferatoractivated receptor gamma Pro12Ala gene polymorphism with type 2 diabetic nephropathy risk in Caucasian population. J Receptor Signal Transduction Research. 2014; 34: 180-184.
46. Hadigan C, Kottilil S. Hepatitis C virus infection and coinfection with human immunodeficiency virus: Challenges and advancements in management. JAMA. 2011; 306: 294-301.
47. Hiard S, Charlier C, Coppieters W, et al. Patrocles: A database of polymorphic miRNA-mediated gene regulation in vertebrates. Nucleic Acids Res. 2010; 38: D640-D651.
48. Ferre P. The biology of peroxisome proliferator-Activated receptors: Relationship with lipid metabolism and insulin sensitivity. Diabetes. 2004; 53 (suppl 1): S43-S50.
49. Pawlotsky JM. New hepatitis C Therapies: The Toolbox, strategies, and challenges. Gastroenterology. 2014; 146: 1176-1192.
50. Matsuura K, Watanabe T, Tanaka Y. Role of IL28B for chronic hepatitis C treatment toward personalized medicine. J Gastroenterol Hepatol. 2014; 29: 241-249.